MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms MALIBU
- 08 Oct 2019 Status changed from not yet recruiting to recruiting.
- 06 Aug 2019 Planned initiation date changed from 15 Jun 2019 to 15 Sep 2019.
- 02 May 2019 Planned End Date changed from 15 Apr 2027 to 15 Jun 2027.